OP0260 Lower Intestinal Perforations Are More Frequent and Present Untypically in Patients Treated w...
OP0260 Lower Intestinal Perforations Are More Frequent and Present Untypically in Patients Treated with Tocilizumab Compared To Other Biologic or Conventional Synthetic DMARDS
About this item
Full title
Author / Creator
Strangfeld, A. , Richter, A. , Siegmund, B. , Herzer, P. , Rockwitz, K. , Demary, W. , Aringer, M. , Zink, A. and Listing, J.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
More information
Scope and Contents
Contents
BackgroundDuring randomized controlled trials with tocilizumab, an IL-6 inhibitor, perforations of the lower intestinal tract (LIP) occurred only in the exposed patient population, not in the control group. The relevance of this finding for daily practice is unclear because we know little about the background risk for LIP in rheumatoid arthritis (R...
Alternative Titles
Full title
OP0260 Lower Intestinal Perforations Are More Frequent and Present Untypically in Patients Treated with Tocilizumab Compared To Other Biologic or Conventional Synthetic DMARDS
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1902055466
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1902055466
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2016-eular.2901
